Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Michael Kubik"'
Autor:
Anna C. Stoll, Christopher J. Kemp, Joseph R. Patterson, Michael Kubik, Nathan Kuhn, Matthew Benskey, Megan F. Duffy, Kelvin C. Luk, Caryl E. Sortwell
Publikováno v:
Journal of Neuroinflammation, Vol 21, Iss 1, Pp 1-17 (2024)
Abstract Background Parkinson’s disease (PD) is a neurodegenerative disorder that is characterized by the presence of proteinaceous alpha-synuclein (α-syn) inclusions (Lewy bodies), markers of neuroinflammation and the progressive loss of nigrostr
Externí odkaz:
https://doaj.org/article/5679db2e702a49868c1ad5fd724f257f
Autor:
Joseph R. Patterson, Joseph Kochmanski, Anna C. Stoll, Michael Kubik, Christopher J. Kemp, Megan F. Duffy, Kajene Thompson, Jacob W. Howe, Allyson Cole-Strauss, Nathan C. Kuhn, Kathryn M. Miller, Seth Nelson, Christopher U. Onyekpe, John S. Beck, Scott E. Counts, Alison I. Bernstein, Kathy Steece-Collier, Kelvin C. Luk, Caryl E. Sortwell
Publikováno v:
npj Parkinson's Disease, Vol 10, Iss 1, Pp 1-17 (2024)
Abstract Examination of early phases of synucleinopathy when inclusions are present, but long before neurodegeneration occurs, is critical to both understanding disease progression and the development of disease modifying therapies. The rat alpha-syn
Externí odkaz:
https://doaj.org/article/8bde4016617e4debb09532f2fc4a2cc0
Autor:
Joseph R. Patterson, Warren D. Hirst, Jacob W. Howe, Christopher P. Russell, Allyson Cole-Strauss, Christopher J. Kemp, Megan F. Duffy, Jared Lamp, Andrew Umstead, Michael Kubik, Anna C. Stoll, Irving E. Vega, Kathy Steece-Collier, Yi Chen, Anne C. Campbell, Catherine L. Nezich, Kelly E. Glajch, Caryl E. Sortwell
Publikováno v:
npj Parkinson's Disease, Vol 8, Iss 1, Pp 1-14 (2022)
Abstract β2-adrenoreceptor (β2AR) agonists have been associated with a decreased risk of developing Parkinson’s disease (PD) and are hypothesized to decrease expression of both alpha-synuclein mRNA (Snca) and protein (α-syn). Effects of β2AR ag
Externí odkaz:
https://doaj.org/article/1490e19ae927454fbbfea97a835eff52
Autor:
Anna C. Stoll, Christopher J. Kemp, Joseph R. Patterson, Michael Kubik, Nathan Kuhn, Matthew Benskey, Megan F. Duffy, Kelvin Luk, Caryl E. Sortwell
Background: Parkinson’s disease (PD) is a neurodegenerative disorder that is characterized by the presence of proteinaceous alpha-synuclein (α-syn) inclusions (Lewy bodies), markers of neuroinflammation and the progressive loss of nigrostriatal do
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::794644bb70cc6aedec7e984d2ea6b914
https://doi.org/10.21203/rs.3.rs-2890683/v1
https://doi.org/10.21203/rs.3.rs-2890683/v1
Autor:
Vesna Sossi, Joseph R. Patterson, Siobhan McCormick, Christopher J. Kemp, Kathryn M. Miller, Anna C. Stoll, Nathan Kuhn, Michael Kubik, Joseph Kochmanski, Kelvin C. Luk, Caryl E. Sortwell
Publikováno v:
Movement Disorders. 37:1739-1748
Positron emission tomography (PET) imaging in early Parkinson's disease (PD) subjects reveals that increased dopamine (DA) turnover and reduced dopamine transporter (DAT) density precede decreases in DA synthesis and storage. The rat α-synuclein pre
Autor:
Pooja Patel, Omar M. A. El-Agnaf, Christopher P. Russell, Michael Kubik, Joseph R. Patterson, Jacob W. Howe, Caryl E. Sortwell, Megan F. Duffy, Christopher J. Kemp, Kelvin C. Luk
Publikováno v:
Parkinsonism Relat Disord
Background Alpha-synuclein (α-syn) preformed fibril (PFF)-induced pathology can be used to study the features and progression of synucleinopathies, such as Parkinson's disease. Intrastriatal injection of mouse α-syn PFFs produce accumulation of α-
Publikováno v:
Classical World. 111:575-576
Publikováno v:
Classical World. 111:579-580
Publikováno v:
Clinical Pharmacology & Therapeutics. 25:25-32
After a control period on a placebo, 45 patients with mild to moderate hypertension were treated with metoprolol, 100 mg twice daily alone and in free combination with chlorthalidone 50 mg daily using a double-blind crossover technique. The beta-bloc
Autor:
M Michael Kubik, Marion Joshi
Publikováno v:
Journal of International Medical Research. 5:83-86
In a double blind trial, 279 patients who had a myocardial infarction less than eighteen hours previously were divided into three groups and given tablets of Practolol, 50 mg 6- hourly, D-Propranolol, 50 mg 6- hourly and Placebo respectively for 5 da